Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALDX

Aldeyra Therapeutics Inc

Mar 11 • 04:00PM ET

6.92

Dollar change +0.30
Percentage change 4.53	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX IONS XOMA PRTA CRBP ITCI BHVN AUPH ACAD RIGL

| Held by: VTI IWM VXF IWN VTWO IWC VHT DFAS ITOT IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.94	Insider Own	2.90%	Shs Outstand	59.65M	Perf Week	12.16%
Market Cap	413.18M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	0.05%	Shs Float	57.98M	Perf Month	16.69%
Income	-55.85M	PEG	-	EPS next Q	-0.24	Inst Own	62.59%	Short Float	6.34%	Perf Quarter	39.80%
Sales	0.00M	P/S	-	EPS this Y	98.02%	Inst Trans	6.43%	Short Ratio	8.24	Perf Half Y	12.89%
Book/sh	1.19	P/B	5.81	EPS next Y	-2990.84%	ROA	-44.16%	Short Interest	3.68M	Perf Year	79.74%
Cash/sh	1.69	P/C	4.08	EPS next 5Y	-	ROE	-58.54%	52W Range	2.71 - 6.92	Perf YTD	38.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.99%	ROI	-64.94%	52W High	0.00%	Beta	0.84
Dividend TTM	-	Quick Ratio	5.48	Sales past 5Y	0.00%	Gross Margin	-	52W Low	155.35%	ATR (14)	0.47
Dividend Ex-Date	-	Current Ratio	5.48	EPS Y/Y TTM	-47.28%	Oper. Margin	-	RSI (14)	63.36	Volatility	6.81% 8.15%
Employees	9	Debt/Eq	0.22	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.29
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	-230.51%	Payout	-	Rel Volume	1.44	Prev Close	6.62
Sales Surprise	-	EPS Surprise	-0.34%	Sales Q/Q	-	Earnings	Mar 06	Avg Volume	446.21K	Price	6.92
SMA20	8.70%	SMA50	22.35%	SMA200	39.48%	Trades		Volume	641,911	Change	4.53%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform	$10
Apr-02-24	Resumed	H.C. Wainwright	Buy	$10
Apr-27-22	Resumed	H.C. Wainwright	Buy	$15
Feb-08-21	Initiated	H.C. Wainwright	Buy	$26
Dec-16-20	Initiated	Berenberg	Buy	$32
Oct-30-20	Initiated	Jefferies	Buy	$24
Oct-16-20	Initiated	BTIG Research	Buy	$29
Sep-22-20	Initiated	Alliance Global Partners	Buy	$32
May-12-20	Initiated	Oppenheimer	Outperform	$12
Dec-04-18	Initiated	Citigroup	Buy	$23
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight	$23 → $30
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy	$13
Sep-26-16	Initiated	H.C. Wainwright	Buy	$18
Jul-01-16	Initiated	Stifel	Buy	$16
Jul-01-15	Initiated	Canaccord Genuity	Buy	$16
Mar-25-15	Initiated	Chardan Capital Markets	Buy	$16
Mar-20-15	Reiterated	H.C. Wainwright	Buy	$13 → $14
Nov-18-14	Initiated	H.C. Wainwright	Buy	$13
Jun-19-14	Initiated	Aegis Capital	Buy	$35

Show Previous Ratings

Mar-10-25 07:00AM	Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference (Business Wire)
Feb-05-25 03:24AM	Aldeyra Therapeutics, Inc. (ALDX) Notice: Grabar Law Office Is Investigating Claims for Long-Term Shareholders (Newsfile) +6.73%
Feb-04-25 07:00AM	Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-20-25 03:28PM	Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-09-24 10:05AM	Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? (Zacks)
07:00AM	Loading…
Dec-02-24 07:00AM	Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-18-24 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement (Business Wire) +11.64%
Nov-14-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-31-24 07:00AM	Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting (Business Wire)
Oct-03-24 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Sep-05-24 07:00AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-30-24 10:38AM	Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory (Insider Monkey) +7.07%
Aug-09-24 06:32AM	Aldeyras Phase III clinical trial of Reproxalap meets primary endpoint (Clinical Trials Arena) +21.72%
Aug-08-24 07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap (Business Wire) +28.53%
Aug-07-24 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap (Business Wire) -5.23%
07:00AM	Loading…
Jun-20-24 07:00AM	Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable (Business Wire) -6.47%
Jun-14-24 06:32AM	Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial (Clinical Trials Arena)
Jun-13-24 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease (Business Wire)
Jun-12-24 07:00AM	Aldeyra Therapeutics to Host Investor Roundtable Q&A (Business Wire)
May-29-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? (Zacks) +12.70%
May-08-24 03:12PM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study (MT Newswires)
07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease (Business Wire)
May-03-24 08:52AM	ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
Apr-25-24 07:00AM	Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day (Business Wire)
Apr-22-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-18-24 07:00AM	Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 (Business Wire)
Apr-06-24 06:37AM	Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why (Zacks)
Apr-04-24 12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal) +12.89%
Apr-03-24 02:58PM	Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval (Barrons.com) +16.90%
07:00AM	Loading…
Mar-28-24 07:00AM	Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease (Business Wire) +6.17%
Mar-27-24 01:21PM	Notice to Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors (Newsfile) +5.48%
Mar-13-24 02:33AM	Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares (GuruFocus.com)
Mar-06-24 09:40AM	Here's Why You Should Invest in Aldeyra (ALDX) Stock Now (Zacks)
Feb-06-24 07:00AM	Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +7.05%
Jan-04-24 07:00AM	Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases (Business Wire)
Dec-19-23 07:27AM	UPDATE 1-Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study (Reuters) +18.58%
07:05AM	Aldeyra Therapeutics' eczema drug succeeds in mid-stage study (Reuters)
07:00AM	Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX629 in Patients with Atopic Dermatitis (Business Wire)
Dec-18-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis (Business Wire)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Dec-05-23 09:00AM	Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings? (Zacks)
Nov-27-23 04:07PM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Nov-01-23 10:34AM	Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? (InvestorPlace) +48.54%
07:05AM	Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -5.98%
Oct-17-23 10:13AM	Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback (Zacks)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Jul-20-23 09:55AM	Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jul-06-23 07:00AM	Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum (Business Wire)
Jun-29-23 07:00AM	Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX2191 in Patients with Retinitis Pigmentosa (Business Wire)
05:20AM	The Petri Dish: Startup behind VR treatments gets $16M, Aldeyra notches midstage trial win (American City Business Journals)
Jun-28-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa (Business Wire)
Jun-27-23 12:03PM	Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo (Benzinga)
07:00AM	Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX629 in Patients With Chronic Cough (Business Wire)
Jun-26-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX629 in Patients with Chronic Cough (Business Wire) +5.63%
Jun-23-23 07:00AM	Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -8.26%
Jun-21-23 09:34AM	Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 (Business Wire) -27.44%
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
Jun-15-23 02:52PM	Why Aldeyra Therapeutics Stock Is Trading Higher Today (Benzinga)
07:08AM	Aldeyra Therapeutics eye treatment meets late-stage study main goal (Reuters)
07:00AM	Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE2 Trial of Reproxalap in Allergic Conjunctivitis (Business Wire)
Jun-14-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE2 Trial in Allergic Conjunctivitis (Business Wire)
Jun-02-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (Business Wire)
May-07-23 07:30AM	This Biotech Is a Sight for Sore Eyes (TheStreet.com)
May-04-23 07:00AM	Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights (Business Wire)
Apr-13-23 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis (Business Wire)
Apr-06-23 07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis (Business Wire)
Mar-30-23 07:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough (Business Wire)
Mar-16-23 07:00AM	Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX2191 in Retinitis Pigmentosa (Business Wire)
Mar-11-23 02:59AM	Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 11:05PM	Q4 2022 Aldeyra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.19% -9.11%
07:00AM	Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (Business Wire)
Mar-02-23 07:00AM	FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +5.78%
Mar-01-23 07:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Feb-28-23 03:22PM	Aldeyra Highlights 12-Month Safety Data Of Reproxalap In Dry Eye Disease Patients (Benzinga) -5.06%
07:00AM	Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease (Business Wire)
Feb-23-23 07:00AM	Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy (Business Wire) +5.91%
Feb-22-23 05:26AM	Owning 40% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), (Simply Wall St.)
Feb-16-23 07:00AM	Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX629 Into New Phase 2 Systemic Disease Trials (Business Wire) +5.46%
Feb-09-23 07:00AM	Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease (Business Wire) +9.37%
Jan-12-23 06:37AM	Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit (Simply Wall St.) +7.29%
Dec-21-22 07:00AM	Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX2191 for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +6.23%
Dec-13-22 01:37PM	Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication (Benzinga)
08:00AM	Aldeyra Therapeutics Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial (Business Wire)
Dec-01-22 08:00AM	Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA (Business Wire) +10.00%
Nov-29-22 08:00AM	Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire) +5.00%
Nov-10-22 07:00AM	Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights (Business Wire) +6.18%
Nov-03-22 08:00AM	Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights (Business Wire)
Nov-02-22 01:45PM	Aldeyra Therapeutics Is a Speculative Stock Worth a Small Position (TheStreet.com)
Oct-26-22 08:00AM	Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting (Business Wire) +7.81%
Oct-06-22 12:23PM	Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder (Benzinga)
07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Oct-05-22 04:05PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy (Business Wire)
Sep-14-22 08:00AM	Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones (Business Wire)
Sep-07-22 08:00AM	Aldeyra Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Sep-01-22 06:56AM	Owning 48% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), (Simply Wall St.)
Aug-15-22 09:55AM	Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Aug-07-22 03:00AM	Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript (Motley Fool)

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Machatha Stephen	Chief Development Officer	Aug 12 '24	Sale	4.74	16,041	75,975	236,771	Aug 14 04:24 PM
Greenberg Bruce	See Remarks	Aug 12 '24	Sale	4.74	10,834	51,313	126,382	Aug 14 04:24 PM
Greenberg Bruce	Officer	Aug 12 '24	Proposed Sale	5.10	10,834	55,253		Aug 12 06:07 PM
Machatha Stephen	Officer	Aug 12 '24	Proposed Sale	5.10	16,041	81,809		Aug 12 05:45 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 04 '24	Buy	4.67	140,281	655,112	9,238,139	Apr 08 05:32 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 05 '24	Buy	4.74	37,712	178,755	9,275,851	Apr 08 05:32 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 03 '24	Buy	4.09	309,847	1,267,274	9,097,858	Apr 03 05:22 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 02 '24	Buy	3.44	186,051	640,015	8,788,011	Apr 03 05:22 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 01 '24	Buy	3.25	8,374	27,216	8,601,960	Apr 03 05:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALDX

Aldeyra Therapeutics Inc

Upgrade your FINVIZ experience